Amyloid PET is a nuclear medicine technique that uses a tracer that binds to the amyloid β (Aβ) protein deposits in the brain, including the Aβ plaques typically observed in patients with Alzheimer's disease.
Carbon-11 labelled Pittsburgh compound B [C-11]PiB was the first radiotracer developed to specifically bind to β-amyloid plaques. Because of its short half-life (20 minutes) and the need for an onsite cyclotron, its use in clinical practice was limited. Radiopharmaceutical based on fluorine-18, with a 110-minute half-life, have been developed. The first clinical amyloid PET tracer, [F-18]florbetapir, was approved by the FDA in 2012.
Benefit from the most advanced brain imaging techniques.